JAK2 V617F Mutation and t(8;21) Positive Acute Myeloid Leukemia After Renal Transplantation

There is an increased risk of malignancy after solid organ transplantation. Acute myeloid leukemia is one of these malignancies. The translocation (8;21) is one of the most frequent karyotypic abnormalities in acute myeloid leukemia. The JAK2 V617F mutation is rarely seen in cases of de novo acute myeloid leukemia. There is no case with translocation (8;21) and JAK2 V617F mutation-positive acute myeloid leukemia after kidney transplantation in the literature. We report a 43 years old female patient who had a kidney transplant from her brother 10 years ago applied to our clinic with the complaint of fatigue. The JAK2 V617 mutation and translocation t(8;21) positive acute myeloid leukemia was detected in this patient. The patient received 3+7 remission induction treatments. After chemotherapy, translocation (8,21) and JAK2 V617F mutation were negative. Acute myeloid leukemia cases developing after kidney transplantation should be evaluated in terms of JAK2V617F mutation positivity.

Böbrek Nakli Sonrasý JAK2 V617F Mutasyonu ve t(8;21) Pozitif Akut Miyeloid Lösemi

Solid organ transplantasyonundan sonra malignite riski artar. Akut miyeloid lösemi bu malignitelerden biridir. Translokasyon (8;21), akut miyeloid lösemide en sýk görülen karyotipik anormalliklerden biridir. JAK2 V617F mutasyonu, de novo akut miyeloid lösemi vakalarýnda nadiren görülür. Literatürde böbrek nakli sonrasý translokasyon (8;21) ve JAK2 V617F mutasyon pozitif akut miyeloid lösemi geliþen bir olgu yoktur. 10 yýl önce kardeþinden böbrek nakli olan 43 yaþýnda halsizlik þikayeti ile kliniðimize baþvuran kadýn hastayý sunduk. Bu hastada JAK2 V617 mutasyonu ve translokasyon t(8;21) pozitif akut miyeloid lösemi tespit edildi. Hasta 3+7 remisyon indüksiyon tedavisi aldý. Kemoterapi sonrasý translokasyon (8,21) ve JAK2 V617F mutasyonu negatifti. Böbrek nakli sonrasý geliþen akut miyeloid lösemi olgularý JAK2V617F mutasyon pozitifliði açýsýndan deðerlendirilmelidir.